Ionis Pharmaceuticals (IONS) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Ionis Pharmaceuticals (NASDAQ: IONS):

• 8/12/2025 – Ionis Pharmaceuticals had its price target raised by analysts at UBS Group AG from $45.00 to $46.00. They now have a “neutral” rating on the stock.
• 7/31/2025 – Ionis Pharmaceuticals had its price target raised by analysts at Raymond James Financial, Inc. from $60.00 to $64.00. They now have a “strong-buy” rating on the stock.
• 7/31/2025 – Ionis Pharmaceuticals was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $62.00 price target on the stock, up previously from $55.00.
• 7/31/2025 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock, up previously from $50.00.
• 7/1/2025 – Ionis Pharmaceuticals was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating. They now have a $57.00 price target on the stock, up previously from $51.00.
• 6/26/2025 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.

Ionis Pharmaceuticals Stock Up 4.1%

Ionis Pharmaceuticals stock opened at $43.10 on Thursday. The firm has a market cap of $6.87 billion, a price-to-earnings ratio of -23.42 and a beta of 0.25. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.87 and a quick ratio of 2.86. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $23.95 and a fifty-two week high of $50.43. The firm has a fifty day moving average price of $40.38 and a two-hundred day moving average price of $34.62.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, July 30th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.51. The firm had revenue of $452.00 million during the quarter, compared to analyst estimates of $270.90 million. Ionis Pharmaceuticals had a negative net margin of 28.25% and a negative return on equity of 45.29%. The business’s revenue was up 100.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.45) EPS. As a group, analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Insider Activity

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 2,432 shares of the business’s stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $45.00, for a total transaction of $109,440.00. Following the completion of the transaction, the chief executive officer owned 179,820 shares of the company’s stock, valued at $8,091,900. The trade was a 1.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eugene Schneider sold 9,549 shares of the company’s stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $42.80, for a total transaction of $408,697.20. Following the transaction, the executive vice president directly owned 51,507 shares of the company’s stock, valued at $2,204,499.60. This represents a 15.64% decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,141 shares of company stock worth $1,204,806 in the last 90 days. Insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Allworth Financial LP raised its position in shares of Ionis Pharmaceuticals by 231.8% during the second quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after buying an additional 517 shares during the last quarter. Signaturefd LLC raised its position in shares of Ionis Pharmaceuticals by 45.6% during the first quarter. Signaturefd LLC now owns 1,382 shares of the company’s stock valued at $42,000 after buying an additional 433 shares during the last quarter. Raiffeisen Bank International AG acquired a new position in shares of Ionis Pharmaceuticals during the fourth quarter valued at about $62,000. Parallel Advisors LLC raised its position in shares of Ionis Pharmaceuticals by 151.3% during the second quarter. Parallel Advisors LLC now owns 1,872 shares of the company’s stock valued at $74,000 after buying an additional 1,127 shares during the last quarter. Finally, Ancora Advisors LLC acquired a new position in shares of Ionis Pharmaceuticals during the first quarter valued at about $60,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.